Releases
ANEB
--
0.00%
--
  • All
  • Financials
  • Insiders
Webull provides the latest Anebulo Pharmaceuticals, Inc. (ANEB) stock and general news. This information may help you make smarter investment decisions.
About ANEB
Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing solutions for people suffering from cannabinoid overdose and substance addiction. The Company's lead product candidate, ANEB-001, is a potent, small molecule cannabinoid receptor antagonist, designed to address the unmet medical need for a specific antidote for cannabinoid overdose. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations. ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within one hour of administration. CB1 antagonists bind to the CB-1 receptor and thereby reverse the action of cannabinoids such as tetrahydrocannabinol (THC). It has completed Phase I trials.